<DOC>
	<DOCNO>NCT02562079</DOCNO>
	<brief_summary>It study basic research mechanistically objectives include clinical biological sample .</brief_summary>
	<brief_title>Vasculopathy , Inflammation Systemic Sclerosis</brief_title>
	<detailed_description>Systemic sclerosis ( SSc ) rare severe disease characterise fibrotic process incompletely elucidate physiopathology . Several share featured identified SSc another autoimmune disease , systemic lupus erythematous ( SLE ) interferon-alpha signature , role platelet polymorphism OX40 ligand ( OX40L ) . In SLE , OX40L show highly link active form disease , increase CD40L platelet induce CD8 cytotoxicity inhibit suppressive function regulator T lymphocyte . The third main factor SSc physiopathology apart autoimmunity fibrosis vasculopathy important role endothelial cell ( EC ) . They turn half-professional antigen present cell modulate adaptive immunity .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<criteria>Age 18 75 . SSc diagnose accord American College Rheumatology ( ACR ) criterion . With skin manifestation since less 10 year . Localised sclerosis ( LSc ) diagnose , morphea type . Age inferior 18 upper 75 . Skin manifestation since 10 year . Haemostasis disease ( independent treatment ) . Stem cell transplant . Immunosuppressive treatment last 6 month . Associate autoimmune disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>T lymphocyte</keyword>
	<keyword>OX40/OX40L</keyword>
</DOC>